Abstract
Introduction
Healthcare payers around the world are desperate to fi nd ways to contain
pharmaceutical expenditures without compromising the quality of the services
they provide This cost-conscious climate has stimulated vigorous growth in the
generics market: from 2003 through 2007, sales of generics in eight leading
pharmaceutical markets grew by an average of 101% per year - double the rate
of growth for nongenerics Manufacturers of branded drugs that face patent
expiration need to be familiar with patterns of generic erosion in the major
markets - in particular, the impact of generics competition on pricing and
market share trends The 45 fi gures and tables in this chartbook - a
substantially expanded update of our 2007 report - provide this critical
analysis
Get the Answers You Need to Shape Your Strategy
- The United States has the world' s largest and reputedly most aggressive
generics market What effect has generics competition had on brand and generics
prices? How rapid is generic erosion of branded drugs' market share? What are
US payers doing to promote greater use of generics?
- Northern European markets are highly mature and characterized by
aggressive generics erosion How rapid is price erosion in Germany? How large
are price differentials between generics and branded drugs in Germany? How has
the United Kingdom' s strong generic prescribing culture infl uenced the rate
of generic erosion in that country?
- Southern European generics markets have the reputation of being highly
conservative What radical changes are transforming the French generics market?
How have Italy' s low prices for branded drugs infl uenced generic erosion?
What measures has the Spanish government taken to stimulate greater use of
generics?
- Japan' s generics market has remained largely underdeveloped despite the
government' s attempts to stimulate greater use of generics How do
manufacturers of branded drugs respond to generics competition in a market
that routinely cuts prices every other year? What market share do brands
retain after three years of generics competition? What is the Japanese
government
- doing to boost the generics market?
Scope
- General environment: penetration of generics; measures implemented by
governments and other
- payers to stimulate the use of generics; acceptance of generics
- Pricing trends: impact of generics competition on the brand,
weighted-average generic, and lowestpriced
- generic prices over time
- Market trends: generics' erosion of branded drugs share of sales and
dispensed units of 32 select
- off-patent compounds
- Outlook and implications for the pharmaceutical industry: payer strategies
to stimulate the use
- of generics; impact of reference pricing; prospects for biosimilars;
defense strategies against generics
- competition; outlook for new drugs
Mentioned in This Spectrum Report
Drugs
- Alendronic acid
- Azithromycin
- Carvedilol
- Cefpodoxime proxetil
- Ceftazidime
- Citalopram
- Clarithromycin
- Epirubicin
- Finasteride
- Fluconazole
- Flumazenil
- Fluticasone
- Formoterol
- Gabapentin
- Glimepiride
- Itraconazole
- Lamotrigine
- Lansoprazole
- Lisinopril
- Meloxicam
- Mirtazapine
- Mitoxantrone
- Omeprazole
- Ondansetron
- Paclitaxel
- Pergolide
- Pravastatin
- Quinapril
- Sertraline
- Simvastatin
- Tamsulosin
- Terbinafi ne
- Zolpidem
Companies
- Abbott Laboratories
- Almirall
- Astellas Pharma
- AstraZeneca
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo,
- Eli Lilly
- Forest Laboratories
- GlaxoSmithKline
- Lundbeck,
- Merck & Co
- Novartis
- Ortho-McNeil-Janssen Pharmaceuticals
- Pfi zer
- Roche
- Sanofi -Aventis
- Schering Plough
- Takeda
- Wyeth
| 
View Cart
